Skip to main content

Table 3 Prevalence of patients meeting the criteria for metabolic syndrome by sulfonylurea status (yes, no)

From: Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Metabolic Syndrome Risk Factors

Tirzepatide 5 mg

Tirzepatide 10 mg

Tirzepatide 15 mg

Comparator

Baseline

Primary Endpoint

Baseline

Primary Endpoint

Baseline

Primary Endpoint

Baseline

Primary Endpoint

SURPASS-4 ± MET ± SGLT2i ± SU vs iGlar, N, yes

156

157

155

466

 ≥ 3 Risk Factors

128 (82.1)

91 (58.3)

141 (89.8)

96 (61.1)

140 (90.3)

84 (54.2)

396 (85.0)

392 (84.1)

WC > 102 cm (M), > 89 cm (F)

124 (79.5)

100 (64.1)

129 (82.2)

96 (61.1)

128 (82.6)

91 (58.7)

359 (77.0)

385 (82.6)

FSG ≥ 100 mg/dL or HbA1c ≥ 5.7%

156 (100.0)

129 (82.7)

157 (100.0)

133 (84.7)

155 (100.0)

119 (76.8)

466 (100.0)

460 (98.7)

SBP > 130 mmHg or DBP > 85 mmHg

96 (61.5)

76 (48.7)

107 (68.2)

85 (54.1)

107 (69.0)

81 (52.3)

296 (63.5)

333 (71.5)

Triglycerides > 150 mg/dL

93 (59.6)

68 (43.6)

82 (52.2)

54 (34.4)

95 (61.3)

51 (32.9)

248 (53.2)

230 (49.4)

HDL < 40 mg/dL (M), < 50 mg/dL (F)

92 (59.0)

77 (49.4)

102 (65.0)

77 (49.0)

94 (60.6)

70 (45.2)

279 (59.9)

261 (56.0)

SURPASS-4 ± MET ± SGLT2i ± SU vs iGlar, N, no

117

119

119

404

 ≥ 3 Risk Factors

99 (84.6)

68 (58.1)

101 (84.9)

67 (56.3)

97 (81.5)

57 (47.9)

331 (81.9)

325 (80.4)

WC > 102 cm (M), > 89 cm (F)

98 (83.8)

74 (63.2)

98 (82.4)

67 (56.3)

98 (82.4)

67 (56.3)

315 (78.0)

324 (80.2)

FSG ≥ 100 mg/dL or HbA1c ≥ 5.7%

117 (100.0)

98 (83.8)

119 (100.0)

94 (79.0)

119 (100.0)

74 (62.2)

403 (99.8)

383 (94.8)

SBP > 130 mmHg or DBP > 85 mmHg

73 (62.4)

58 (49.6)

73 (61.3)

70 (58.8)

72 (60.5)

57 (47.9)

264 (65.3)

276 (68.3)

Triglycerides > 150 mg/dL

61 (52.1)

44 (37.6)

64 (53.8)

38 (31.9)

56 (47.1)

41 (34.5)

203 (50.2)

186 (46.0)

HDL < 40 mg/dL (M), < 50 mg/dL (F)

64 (54.7)

53 (45.3)

80 (67.2)

53 (44.5)

74 (62.2)

54 (45.4)

230 (56.9)

205 (50.7)

  1. Data are n (%) at baseline and at the primary endpoint of 52 weeks (SURPASS-4) in patients on-treatment compliant to study drug (patients taking ≥ 75% of assigned doses). Percentage is calculated based on each subgroup value for each treatment group
  2. DBP: diastolic blood pressure; F: female; FSG: fasting serum glucose; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; iDeg: insulin degludec; iGlar: insulin glargine; M: male; MET: metformin; n: number of patients in the specified category; SBP: systolic blood pressure; SGLT2i: sodium-glucose co-transporter 2 inhibitor; SU: sulfonylurea; WC: waist circumference
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840